Overview
Adult Refsum disease (ARD), also known as classic Refsum disease, heredopathia atactica polyneuritiformis, or phytanic acid storage disease, is a rare inherited disorder of lipid metabolism caused by the accumulation of phytanic acid in blood and tissues. The condition results from a deficiency of the peroxisomal enzyme phytanoyl-CoA hydroxylase (encoded by the PHYH gene) or, less commonly, defects in the PEX7 gene, which is required for importing the enzyme into peroxisomes. Phytanic acid, a branched-chain fatty acid derived exclusively from dietary sources (dairy products, ruminant fats, and certain fish), cannot be properly broken down and accumulates in multiple organ systems. The disease primarily affects the nervous system, eyes, skin, heart, and bones. Cardinal clinical features include retinitis pigmentosa (causing progressive night blindness and visual field constriction), peripheral polyneuropathy (with distal weakness, sensory loss, and absent deep tendon reflexes), cerebellar ataxia, and elevated cerebrospinal fluid protein without increased cell count (albuminocytologic dissociation). Additional features may include ichthyosis (dry, scaly skin), anosmia (loss of smell), sensorineural hearing loss, cardiac arrhythmias and cardiomyopathy, and skeletal abnormalities such as shortened metacarpals or metatarsals. Symptoms typically begin in late childhood or early adulthood, though onset is variable. The cornerstone of treatment is strict lifelong dietary restriction of phytanic acid, which involves limiting intake of dairy fats, ruminant meat fat, and certain fish. When adhered to consistently, dietary management can lower plasma phytanic acid levels, stabilize or improve neurological symptoms, and prevent disease progression. Plasmapheresis or lipid apheresis may be used in acute situations or when phytanic acid levels are dangerously elevated, to rapidly reduce circulating phytanic acid. Rapid weight loss and fasting should be avoided, as mobilization of fat stores can release stored phytanic acid and precipitate acute neurological or cardiac crises. With early diagnosis and consistent dietary management, prognosis can be significantly improved, though existing damage to the retina and nerves may be irreversible.
Also known as:
Clinical phenotype terms— hover any for plain English:
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Variable
Can begin at different ages, from infancy through adulthood
Treatments
No FDA-approved treatments are currently listed for Adult Refsum disease.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Adult Refsum disease at this time.
New trials open frequently. Follow this disease to get notified.
Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Adult Refsum disease.
Community
No community posts yet. Be the first to share your experience with Adult Refsum disease.
Start the conversation →Latest news about Adult Refsum disease
Disease timeline:
New recruiting trial: Association Between Radial Artery Intervention and Development of Neuropathy in the Hand - A Prospective Study
A new clinical trial is recruiting patients for Adult Refsum disease
New recruiting trial: Spastic Paraplegia - Centers of Excellence Research Network
A new clinical trial is recruiting patients for Adult Refsum disease
New recruiting trial: Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia
A new clinical trial is recruiting patients for Adult Refsum disease
New recruiting trial: The preSPG4 Study - Studying the Prodromal and Early Phase of SPG4
A new clinical trial is recruiting patients for Adult Refsum disease
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Adult Refsum disease
What is Adult Refsum disease?
Adult Refsum disease (ARD), also known as classic Refsum disease, heredopathia atactica polyneuritiformis, or phytanic acid storage disease, is a rare inherited disorder of lipid metabolism caused by the accumulation of phytanic acid in blood and tissues. The condition results from a deficiency of the peroxisomal enzyme phytanoyl-CoA hydroxylase (encoded by the PHYH gene) or, less commonly, defects in the PEX7 gene, which is required for importing the enzyme into peroxisomes. Phytanic acid, a branched-chain fatty acid derived exclusively from dietary sources (dairy products, ruminant fats, and
How is Adult Refsum disease inherited?
Adult Refsum disease follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
Which specialists treat Adult Refsum disease?
23 specialists and care centers treating Adult Refsum disease are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.